The Middle East and Africa (MEA) biologics and biosimilars market is poised for substantial growth, with an expected valuation of US$ 512.6 million in 2023. The market is projected to expand at a compound annual growth rate (CAGR) of 5.5%, reaching approximately US$ 875.6 million by 2033. According to a recent study by Future Market Insights, adalimumab currently leads the drug segment, capturing about 36.7% of the market share in 2022.
Several factors are driving the growth of the biologics and biosimilars market in the MEA region. The rising prevalence of chronic diseases, increasing demand for cost-effective treatment options, and growing healthcare infrastructure are significant contributors to market expansion. As healthcare providers and patients seek effective therapies, the adoption of biologics and biosimilars continues to rise, offering alternatives to traditional medications.
Adalimumab, a monoclonal antibody used to treat various autoimmune conditions, remains a key player in the market, reflecting the increasing acceptance of biosimilars in the treatment landscape. The success of adalimumab highlights the potential for biosimilars to provide affordable and effective treatment options for patients.
North Africa and the Middle East are expected to drive growth in this market, supported by governmental initiatives to enhance healthcare access, investments in biotechnology, and collaborations with pharmaceutical companies.
As the biologics and biosimilars market continues to evolve, industry players are likely to focus on innovation, expanding their product portfolios, and enhancing patient access to these therapies. The future of the MEA biologics and biosimilars market looks promising, offering opportunities for improved patient outcomes and advancements in healthcare delivery across the region.
Sales Analysis of MEA Biologics and Biosimilar Market from 2017 to 2022 Vs Market Outlook for 2023 to 2033
The market value for MEA biologics and biosimilar market was approximately 3.1% of the overall ~US$ 15.4 Billion global biologics and biosimilar market in 2021.
The most common cancers are breast cancer, lung and bronchus, colon and rectum, prostate, stomach, liver, cervix uteri, oesophagus, thyroid, and bladder.
to improve cancer patient care and ensure sure they have access to more effective, convenient, and affordable treatment options. MEA’s expansion in oncology innovation is being fuelled by a flurry of new, oncology–focused biotech businesses and increased cancer research.
due to the rising incidence of numerous cancers, the market for biosimilar drugs is anticipated to expand in this region.
Manufacturers of biologics are adopting various strategies to respond to potential entrants in biosimilars.
Pharmaceutical manufacturers are concentrating on ways to broaden and improve formulations, dosing, expression systems, and delivery mechanisms.
For MabThera, for instance, Roche created a novel subcutaneous formulation that reduces treatment time from 2.5 hours to 5 minutes. This can enhance patient adherence and healthcare results.
To remain competitive and ensure a robust product pipeline, leading biopharmaceutical companies are continuing to focus on the development of innovative drugs associated with regular treatments and technologically advanced healthcare solutions to increase the adoption rate.
What are the Key Opportunities for the Manufacturers Operating in MEA Biologics and Biosimilar Market?
Ustekinumab surpassed other medications in terms of annual increases in medical inflation-adjusted prices. Innovative strategies, such as the creation of biosimilars to improve patient access to care, are essential for reducing cost growth above inflation.
Global industry leaders are developing extended indications for already licensed biologics. The strategic approach involves the extension of the indication by conducting additional clinical investigations on the licensed biologics candidate.
The most advanced portfolios of biologics and biosimilars are held by early market leaders including AbbVie, Eisa Co Ltd., and Janssen Pharmaceuticals, a division of Johnson & Johnson.
According to WHO (2022), Non-communicable disease mortality is dramatically increasing in Middle Eastern and African (MEA) nations. 74% of all deaths in MEA are caused due to non-communicable diseases, which cause more than 38 million deaths annually worldwide.
Competitive Landscape
The leading players invest in several product launches, expansions, partnerships, mergers, and acquisitions to increase their market share globally and enhance their business strategies. The major companies in the MEA biologics and biosimilar market have embraced these as their top–tier primary promotional methods.
- Abbott Operations Uruguay S.R.L. and Shanghai Henlius Biotech, Inc. announced their semi-exclusive licencing agreement in May 2022 for the marketing of Henlius’ independently developed HANLIKANG (rituximab) and HANQUYOU (trastuzumab, also known as Zercepac® in Europe) in Brazil.
- Ligand Pharmaceuticals Corporation (Ligand) acquire Pfenex Inc. (Pfenex) in September 2020. Pfenex is a producer of biosimilar medications such teriparatide, ranibizumab, and pegfilgrastim.
Hikma Pharmaceuticals announced in July 2022 that it has signed a marketing agreement for Celltrion’s YuflymaTM drug.
Key Companies Profiled
- AbbVie Inc.
- Eisai Co Ltd
- Zydus Cadila(Cadila Healthcare)
- Amneal Pharmaceuticals, Inc.
- Pfizer Inc.
- Celltrion, Inc.
- Coherus BioSciences, Inc.
- F. Hoffmann–La Roche Ltd (Genentech, Inc.)
- Alexion(Astrazeneca)
- Johnson & Johnson
- Amgen
- Hikma pharmaceuticals plc.
Key Market Segments Covered in MEA Biologics and Biosimilar Industry Research
Drug:
- Adalimumab
- Bevacizumab
- Trastuzumab
- Ustekinumab
- Golimumab
- Eculizumab
- Rituximab
Drug Class:
- Antirheumatics
- TNF Alfa Inhibitors
- VEGF/VEGFR Inhibitors
- HER2 Inhibitors
- Selective Immunosuppressant’s
- Interleukin Inhibitors
Dosage Form:
- Subcutaneous
- Intravenous
Indication:
- Cancer
- Arthritis
- Rheumatoid
- Psoriatic
- Others
- Skin Disorders
- Plaque-Type Psoriasis
- Hidradenitis Suppurativa
- Inflammatory Bowel Disease (IBD)
- Crohn’s Disease
- Ulcerative Colitis
- Rare Disease
- Others
Distribution Channel:
- Hospitals
- Specialty Clinics
- Cancer Research Centers
- Retail Sales
- Retail Pharmacies
- Mail Order Pharmacies /Online Sales
Country:
- UAE
- Bahrain
- Iraq
- Jordan
- Kuwait
- Lebanon
- Oman
- Qatar
- KSA
- Iran
- Palestine
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube